Warning: The NCBI web site requires JavaScript to function. more...
Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis.
Verstappen SM, Poole AR, Ionescu M, King LE, Abrahamowicz M, Hofman DM, Bijlsma JW, Lafeber FP; Utrecht Rheumatoid Arthritis Cohort Study group (SRU).
Arthritis Res Ther. 2006;8(1):R31. Epub 2006 Jan 10.
Related citations
Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy.
Mullan RH, Matthews C, Bresnihan B, FitzGerald O, King L, Poole AR, Fearon U, Veale DJ.
Arthritis Rheum. 2007 Sep;56(9):2919-28.
Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression.
Syversen SW, Goll GL, van der Heijde D, Landewé R, Gaarder PI, Odegård S, Haavardsholm EA, Kvien TK.
J Rheumatol. 2009 Feb;36(2):266-72.
Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis.
Kong SY, Stabler TV, Criscione LG, Elliott AL, Jordan JM, Kraus VB.
Arthritis Rheum. 2006 Aug;54(8):2496-504.
Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response.
Kim TH, Stone M, Payne U, Zhang X, Ionescu M, Lobanok T, King L, Poole AR, Inman RD.
Arthritis Rheum. 2005 Mar;52(3):885-91.
Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation.
Fraser A, Fearon U, Billinghurst RC, Ionescu M, Reece R, Barwick T, Emery P, Poole AR, Veale DJ.
Arthritis Rheum. 2003 Nov;48(11):3085-95.
Serum concentrations of type II collagen biomarkers (C2C, C1, 2C and CPII) suggest different pathophysiologies in patients with hip osteoarthritis.
Conrozier T, Poole AR, Ferrand F, Mathieu P, Vincent F, Piperno M, Verret C, Ionescu M, Vignon E.
Clin Exp Rheumatol. 2008 May-Jun;26(3):430-5.
Associations between joint space narrowing and molecular markers of collagen and proteoglycan turnover in patients with knee osteoarthritis.
Mazzuca SA, Poole AR, Brandt KD, Katz BP, Lane KA, Lobanok T.
J Rheumatol. 2006 Jun;33(6):1147-51.
Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism.
Månsson B, Carey D, Alini M, Ionescu M, Rosenberg LC, Poole AR, Heinegård D, Saxne T.
J Clin Invest. 1995 Mar;95(3):1071-7.
Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis.
Maksymowych WP, Landewé R, Conner-Spady B, Dougados M, Mielants H, van der Tempel H, Poole AR, Wang N, van der Heijde D.
Arthritis Rheum. 2007 Jun;56(6):1846-53.
Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers.
Cibere J, Thorne A, Kopec JA, Singer J, Canvin J, Robinson DB, Pope J, Hong P, Grant E, Lobanok T, Ionescu M, Poole AR, Esdaile JM.
J Rheumatol. 2005 May;32(5):896-902.
Differences in biomarkers of type II collagen in atrophic and hypertrophic osteoarthritis of the hip: implications for the differing pathobiologies.
Conrozier T, Ferrand F, Poole AR, Verret C, Mathieu P, Ionescu M, Vincent F, Piperno M, Spiegel A, Vignon E.
Osteoarthritis Cartilage. 2007 Apr;15(4):462-7. Epub 2006 Oct 18.
Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study.
Garnero P, Landewé R, Boers M, Verhoeven A, Van Der Linden S, Christgau S, Van Der Heijde D, Boonen A, Geusens P.
Arthritis Rheum. 2002 Nov;46(11):2847-56.
Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
Charni N, Juillet F, Garnero P.
Arthritis Rheum. 2005 Apr;52(4):1081-90.
Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers.
Young-Min S, Cawston T, Marshall N, Coady D, Christgau S, Saxne T, Robins S, Griffiths I.
Arthritis Rheum. 2007 Oct;56(10):3236-47.
Relationships of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis.
Ishiguro N, Ito T, Oguchi T, Kojima T, Iwata H, Ionescu M, Poole AR.
Arthritis Rheum. 2001 Nov;44(11):2503-11.
Analysis of cartilage biomarkers in the early phases of canine experimental osteoarthritis.
Matyas JR, Atley L, Ionescu M, Eyre DR, Poole AR.
Arthritis Rheum. 2004 Feb;50(2):543-52.
Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis.
Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, Delmas PD.
Arthritis Rheum. 2002 Oct;46(10):2613-24.
The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy.
Jansen NW, Roosendaal G, Lundin B, Heijnen L, Mauser-Bunschoten E, Bijlsma JW, Theobald M, Lafeber FP.
Arthritis Rheum. 2009 Jan;60(1):290-8.
Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
Garnero P, Gineyts E, Christgau S, Finck B, Delmas PD.
Arthritis Rheum. 2002 Jan;46(1):21-30.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on